| Objective:In this study,according to the guidelines for diagnosis and treatment of tumor in traditional Chinese medicine and the clinical experience of the tutor,the clinical effect and safety of Jiawei Liujunzi Decoction on the patients with spleen and stomach weakness syndrome after breast cancer operation after ec chemotherapy were observed,the therapeutic effect was analyzed,the role of Jiawei Liujunzi Decoction in spleen and stomach weakness syndrome of breast cancer was discussed,and the treatment process of combined traditional Chinesemedicine was evaluated So as to provide clinical reference for the treatment of breast cancer by TCM combined with modern medicine.Methods:From January 2019 to January 2020,60 eligible breast cancer patients who were treated in the Department of oncology,breast surgery and Cancer Hospital of Jiangsu Province were collected and the treatment group is separated from the control group on the basis of the design method of parallel control.There were 30 patients in the treatment group and the control group respectively.The control group was treated with ec chemotherapy.On this basis,the treatment groupwas treated with Jiawei Liujunzi Decoction before and after the treatment,the chemotherapy effect,TCM syndrome effect,physical condition,quality of life and side effects were watched,and spss19.0 software was used to analyze the data.Results:1.Short term efficacy:the objective effective rates of the treatment group and the control group were 20%and 16.67%respectively,and the disease control rates were 93.33%and 83.33%respectively.there was no difference in the two groups(P=0.479>0.05).2.Syndrome of traditional Chinese medicine:the integral of spleen and stomach asthenia syndrome in the two groups declined significantly after treatment(P=0<0.01),and the treatment group improved significantly compared with the control group(P=-0.015<0.05);in the aspect of syndrome improvement of traditional Chinese medicine,the total effective rate of the two groups were70%and 40%,respectively,and the improvement of spleen and stomach asthenia syndrome in the treatment group was superior to the control group(P=0.036<0.05).the specific symptoms of the treatment group were improved after treatment(P<0.05);the control group was improved after treatment(P<0.05);the two groups were improved after treatment(P<0.05);there have no statistical difference(P<0.05).3.KPS score:after treatment,KPS score in the treatment group was significantly higher(P=0.031<0.05),but there was no statistical difference in the control group.the total KPS score in the treatment group(P=0.003<0.05)and the improvement of KPS after treatment were better than that in the control group(P=0.007<0.05).4.QLQ-C30 score table:there were statistical differences in body function,fatigue,nausea and vomiting,anorexia and diarrhea before and after treatment in the treatment group(P=0<0.05);there were statistical differences in body function,nausea and vomiting pre therapy and post-treatment in the control group(P=0<0.05);there were significant differences in body function,fatigue,anorexia and diarrhea after treatment in the two groups(P=0<0.05).5.FACT-B score table:there were statistical differences in physiological status(P=0),functional status(P=0.003)and total score(P=0)before and after treatment in the treatment group;there were statistical differences in physiological status(P=0.041),total score(P=0.035)pre therapy and post-treatment in the control group;there were statistical imparities in physiological status(P=0.024),functional status(P=0)and total score(P=0.033)after treatment in the two groups.6.Toxic and side effects:there was no statistical difference in hemoglobin,leukocyte,neutrophil absolute value,platelet,GPT,GST,bun and creatinine between the two groups after treatment(P>0.05);there was statistical difference in hemoglobin,WBC,neutrophil and GST in the treatment group pre therapy and post-treatment(P<0.05),and in the white in the control group pre therapy and post-treatment(P<0.05)there were obvious differences in cell,neutrophil,platelet and glutamic oxaloacetylase(P<0.05).the treatment group has advantages in increasing hemoglobin,preventing the decrease of platelets and the increase of GPT after chemotherapy,but not in reducing the absolute value of leukocytes and medium and fine-grained cells and increasing of GST,bun and creatinine after chemotherapy.Conclusion:Jiawei Liujunzi Decoction Combined with ec chemotherapy has no advantage in the short-term efficacy of the patients with spleen and stomach weakness syndrome after breast cancer operation,but it has some advantages in improving the symptoms of spleen and stomach weakness,improving the physical condition and quality of life,and it can partially alleviate the bone marrow inhibition and hepatorenal toxicity in chemotherapy,playing a role of increasing efficiency and reducing toxicity. |
PDF Full Text Request